We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Thermo Fisher Scientific (TMO) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Thermo Fisher Scientific (TMO - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Thermo Fisher Scientific is a member of the Medical sector. This group includes 1122 individual stocks and currently holds a Zacks Sector Rank of #15. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. TMO is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for TMO's full-year earnings has moved 0.22% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, TMO has moved about 24.24% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of -8.58% on a year-to-date basis. As we can see, Thermo Fisher Scientific is performing better than its sector in the calendar year.
Looking more specifically, TMO belongs to the Medical - Instruments industry, which includes 101 individual stocks and currently sits at #155 in the Zacks Industry Rank. On average, stocks in this group have gained 5.68% this year, meaning that TMO is performing better in terms of year-to-date returns.
TMO will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
View the Zacks #1 Rank List
Image: Bigstock
Is Thermo Fisher Scientific (TMO) Outperforming Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of Thermo Fisher Scientific (TMO - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Thermo Fisher Scientific is a member of the Medical sector. This group includes 1122 individual stocks and currently holds a Zacks Sector Rank of #15. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. TMO is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for TMO's full-year earnings has moved 0.22% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, TMO has moved about 24.24% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of -8.58% on a year-to-date basis. As we can see, Thermo Fisher Scientific is performing better than its sector in the calendar year.
Looking more specifically, TMO belongs to the Medical - Instruments industry, which includes 101 individual stocks and currently sits at #155 in the Zacks Industry Rank. On average, stocks in this group have gained 5.68% this year, meaning that TMO is performing better in terms of year-to-date returns.
TMO will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.